# Study of Safety and Efficacy of Doxercalciferol in Patients With Chronic Kidney Disease, Stage 3 or 4, and Secondary Hyperparathyroidism

> **NCT00123461** · PHASE4 · COMPLETED · sponsor: **Genzyme, a Sanofi Company** · enrollment: 70 (estimated)

## Conditions studied

- Secondary Hyperparathyroidism
- Renal Failure
- Chronic Renal Insufficiency

## Interventions

- **DRUG:** Hectorol (doxercalciferol capsules), 0.5mcg

## Key facts

- **NCT ID:** NCT00123461
- **Lead sponsor:** Genzyme, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-07
- **Primary completion:** 2007-10
- **Final completion:** 2007-10
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2015-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00123461

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00123461, "Study of Safety and Efficacy of Doxercalciferol in Patients With Chronic Kidney Disease, Stage 3 or 4, and Secondary Hyperparathyroidism". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00123461. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*